| FDA approves saxagliptin (Onglyza) labeling to include patients with CKD |
|
| Bloomberg: Bristol-Myers Squibb Co. and AstraZeneca PLC said Wednesday they are expanding the label of their diabetes drug Onglyza, adding information about the drug's effects in patients with kidney failure. |